OpRegen

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Age-Related Macular DegenerationGeographic Atrophy

43 competitors in Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

1

Eylea

Regeneron

Approved

402

Zometa

Pfizer

Approved

—3

Plavix

Sanofi

Approved

—4

Bayer Aspirin

Bayer

Approved

—5

Tecfidera

Biogen

Approved

—6

Visudyne

BBausch Health Americas, Inc.

Approved

17

Lodosyn

LLaTonya J. Hickson

Approved

—8

Bendopa

MMerz North America, Inc.

Approved

—9

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—10

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—Show 25 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Geographic Atrophy1 trial

A Phase IIa, Multicenter, Open-label, Single-Arm Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Recruiting·Roche·Phase 2·NCT05626114·60 enrolled

Age-Related Macular Degeneration1 trial

Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients With Advanced Dry-Form Age-Related Macular Degeneration (Geographic Atrophy)

Active, not recruiting·Roche·Preclinical·NCT02286089·24 enrolled

Details

Drug Info

Related News